Imperial College London

Privately held: no public share price · United Kingdom

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Fatty acid synthase (FASN)Radiopharmaceutical
Brain Metastases

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 July 2026Topline resultRAD101RAD101 Phase 2b meets primary endpoint
US · Radiopharm Theranostics, Ltd · Source ↗

Financial reports

No financial reports recorded.